Why does androgen deprivation enhance the results of radiation therapy?-Reference-Cited by-同舟云学术

Why does androgen deprivation enhance the results of radiation therapy?

Published:2008-09 Issue:5 Volume:26 Page:522-529
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Wo Jennifer Y.,Zietman Anthony L.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference50 articles.

1. Prostatic cancer;Huggins;Arch Surg,1941

2. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation sdjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate;Pilepich;IJROBP,2001

3. Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial;D'Amico;JAMA,2004

4. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma;Witjes;Urology,1997

5. Neoadjuvant hormonal therapy: The Canadian experience;Labrie;Urology,1997

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

2. Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer;International Journal of Molecular Sciences;2023-12-20

3. Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis;Clinical and Translational Radiation Oncology;2023-01

4. Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment;Handbook of Oncobiology: From Basic to Clinical Sciences;2023

5. PARP inhibitors in metastatic prostate cancer: When, who, and how?;International Journal of Molecular and Immuno Oncology;2022-09-23